BEBT-303

BEBT-303

   Indoleamine-(2,3)-dioxygenase (IDO ) is one of several immune checkpoint proteins involved in tumor immune escape. The IDO enzyme, activated in dendritic cells (DC) and macrophages (Mφ), leads to tryptophan depletion and production of kynurenine, resulting in effector T-cell apoptosis/dysfunction and immunosuppressive regulatory T-cell (TReg) induction. IDO1 is the only checkpoint target for small molecule drugs that are currently being evaluated in Clinic. BEBT-303 is a novel IDO1 Inhibitor for which our company owns global IP rights. With significantly improved potency and a favorable oral pharmacokinetics profile over IBCB24360 and NLG919, two IDO1 inhibitors currently in clinical trials in the US,  BEBT-303 is a very competitive IDO1 inhibitor for the clinical development.